The company, clinicians and patients are now calling for a fast listing. OPDIVO, which is currently listed for advanced melanoma, could become one of the first medicines funded from the proceeds of savings currently being negotiated between government and industry.
Latest Video
New Stories
-
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5, Ep .24
July 17, 2026 - - Podcast -
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News

